Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

Prostate cancer screening: guidelines review and laboratory issues.

Filella X, Albaladejo MD, Allué JA, Castaño MA, Morell-Garcia D, Ruiz MÀ, Santamaría M, Torrejón MJ, Giménez N.

Clin Chem Lab Med. 2019 May 23. pii: /j/cclm.ahead-of-print/cclm-2018-1252/cclm-2018-1252.xml. doi: 10.1515/cclm-2018-1252. [Epub ahead of print] Review.

PMID:
31120856
2.

Tartrate-resistant acid phosphatase 5b, but not periostin, is useful for assessing Paget's disease of bone.

Guañabens N, Filella X, Florez H, Ruiz-Gaspá S, Conesa A, Peris P, Monegal A, Torres F.

Bone. 2019 Jul;124:132-136. doi: 10.1016/j.bone.2019.04.023. Epub 2019 Apr 30.

PMID:
31051316
3.

Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study.

Huelin P, Solà E, Elia C, Solé C, Risso A, Moreira R, Carol M, Fabrellas N, Bassegoda O, Juanola A, de Prada G, Albertos S, Piano S, Graupera I, Ariza X, Napoleone L, Pose E, Filella X, Morales-Ruiz M, Rios J, Fernández J, Jiménez W, Poch E, Torres F, Ginès P.

Hepatology. 2019 Jul;70(1):319-333. doi: 10.1002/hep.30592. Epub 2019 Apr 25.

PMID:
30810244
4.

Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients.

Xipell M, Montagud-Marrahi E, Rubio MV, Ojeda R, Arias-Guillén M, Fontseré N, Rodas L, Vera M, Broseta JJ, Torregrosa V, Filella X, Maduell F.

Blood Purif. 2019 Jan 30:1-9. doi: 10.1159/000496562. [Epub ahead of print]

PMID:
30699421
5.

Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis.

Foj L, Filella X.

Pathol Oncol Res. 2018 Oct 26. doi: 10.1007/s12253-018-0508-3. [Epub ahead of print]

PMID:
30367364
6.

Novel Biomarkers for Prostate Cancer Detection and Prognosis.

Filella X, Foj L.

Adv Exp Med Biol. 2018;1095:15-39. doi: 10.1007/978-3-319-95693-0_2.

PMID:
30229547
7.

Emerging biomarkers in the diagnosis of prostate cancer.

Filella X, Fernández-Galan E, Fernández Bonifacio R, Foj L.

Pharmgenomics Pers Med. 2018 May 16;11:83-94. doi: 10.2147/PGPM.S136026. eCollection 2018. Review.

8.

[Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians].

Giménez N, Filella X, Gavagnach M, Allué JA, Pedrazas D, Ferrer F; Grupo de Estudio sobre Cribado en Cáncer de Próstata.

Semergen. 2018 Sep;44(6):409-419. doi: 10.1016/j.semerg.2018.02.001. Epub 2018 Mar 21. Spanish.

PMID:
29574008
9.

Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia.

Florez H, Mandelikova S, Filella X, Monegal A, Guañabens N, Peris P.

Med Clin (Barc). 2018 Jul 23;151(2):65-67. doi: 10.1016/j.medcli.2017.11.036. Epub 2017 Dec 30. English, Spanish.

PMID:
29295788
10.

Concordance between direct and indirect measurements of free 25-OH vitamin D.

Peris P, Filella X, Monegal A, Guañabens N, Foj L, Bonet M, Boquet D, Casado E, Cerdá D, Erra A, Gómez-Vaquero C, Martínez S, Montalá N, Pittarch C, Kanterewicz E, Sala M, Suris X, Carrasco JL; LabOscat study group.

Clin Chim Acta. 2017 Dec;475:169-171. doi: 10.1016/j.cca.2017.10.016. Epub 2017 Oct 19.

PMID:
29056531
11.

Analytical verification and method comparison of the ADVIA Centaur® Intact Parathyroid Hormone assay.

Fernández-Galán E, Bedini JL, Filella X.

Clin Biochem. 2017 Dec;50(18):1222-1227. doi: 10.1016/j.clinbiochem.2017.09.006. Epub 2017 Sep 11.

PMID:
28912096
12.

High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma.

Dlouhy I, Filella X, Rovira J, Magnano L, Rivas-Delgado A, Baumann T, Martínez-Trillos A, Balagué O, Martínez A, González-Farre B, Karube K, Gine E, Delgado J, Campo E, López-Guillermo A.

Leuk Res. 2017 Aug;59:20-25. doi: 10.1016/j.leukres.2017.05.014. Epub 2017 May 17.

PMID:
28544905
13.

Comparison of total, free and bioavailable 25-OH vitamin D determinations to evaluate its biological activity in healthy adults: the LabOscat study.

Peris P, Filella X, Monegal A, Guañabens N, Foj L, Bonet M, Boquet D, Casado E, Cerdá D, Erra A, Gómez-Vaquero C, Martínez S, Montalá N, Pittarch C, Kanterewicz E, Sala M, Suris X, Carrasco JL; LabOscat Study Group.

Osteoporos Int. 2017 Aug;28(8):2457-2464. doi: 10.1007/s00198-017-4062-8. Epub 2017 May 2.

PMID:
28466136
14.

Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis.

Foj L, Ferrer F, Serra M, Arévalo A, Gavagnach M, Giménez N, Filella X.

Prostate. 2017 May;77(6):573-583. doi: 10.1002/pros.23295. Epub 2016 Dec 19.

PMID:
27990656
15.

The clinical value of biomarkers in respiratory complications in hematopoietic SCT.

Lucena CM, Rovira M, Gabarrús A, Filella X, Martínez C, Domingo R, Torres A, Agustí C.

Bone Marrow Transplant. 2017 Mar;52(3):415-422. doi: 10.1038/bmt.2016.280. Epub 2016 Oct 31.

PMID:
27797370
16.
17.

Utility of proGRP as a tumor marker in the medullary thyroid carcinoma.

Parra-Robert M, Orois A, Augé JM, Halperin I, Filella X, Molina R.

Clin Chem Lab Med. 2017 Mar 1;55(3):441-446. doi: 10.1515/cclm-2016-0572.

PMID:
27754959
18.

Automated measurement of 25-OH Vitamin D on the LUMIPULSE® G1200: analytical verification and method comparison.

Parra M, Foj L, Filella X.

Br J Biomed Sci. 2016 Jul;73(3):104-109. Epub 2016 Jun 16.

PMID:
27310165
19.

Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.

Magnano L, Fernández de Larrea C, Elena M, Cibeira MT, Tovar N, Aróstegui JI, Pedrosa F, Rosiñol L, Filella X, Yagüe J, Bladé J.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e71-7. doi: 10.1016/j.clml.2016.02.034. Epub 2016 Feb 27.

PMID:
27013181
20.

miRNAs as novel biomarkers in the management of prostate cancer.

Filella X, Foj L.

Clin Chem Lab Med. 2017 May 1;55(5):715-736. doi: 10.1515/cclm-2015-1073. Review.

21.

Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.

Molina R, Marrades RM, Augé JM, Escudero JM, Viñolas N, Reguart N, Ramirez J, Filella X, Molins L, Agustí A.

Am J Respir Crit Care Med. 2016 Feb 15;193(4):427-37. doi: 10.1164/rccm.201404-0603OC.

PMID:
26465739
22.

Identification of Candidates for Active Surveillance: Should We Change the Current Paradigm?

Alcover J, Filella X.

Clin Genitourin Cancer. 2015 Dec;13(6):499-504. doi: 10.1016/j.clgc.2015.06.001. Epub 2015 Jun 16. Review.

PMID:
26194410
23.

Reference intervals for bone turnover markers in Spanish premenopausal women.

Guañabens N, Filella X, Monegal A, Gómez-Vaquero C, Bonet M, Buquet D, Casado E, Cerdá D, Erra A, Martinez S, Montalá N, Pitarch C, Kanterewicz E, Sala M, Surís X, Torres F; LabOscat Study Group.

Clin Chem Lab Med. 2016 Feb;54(2):293-303. doi: 10.1515/cclm-2015-0162.

24.

Emerging biomarkers in the detection and prognosis of prostate cancer.

Filella X, Foj L.

Clin Chem Lab Med. 2015 Jun;53(7):963-73. doi: 10.1515/cclm-2014-0988. Review.

25.

Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.

Gifre L, Vidal J, Carrasco JL, Filella X, Ruiz-Gaspà S, Muxi A, Portell E, Monegal A, Guañabens N, Peris P.

J Bone Miner Res. 2015 Jun;30(6):1014-21. doi: 10.1002/jbmr.2423.

26.

Prospective study of individualized or high fixed doses of vitamin D supplementation after bariatric surgery.

Flores L, Moizé V, Ortega E, Rodríguez L, Andreu A, Filella X, Vidal J.

Obes Surg. 2015 Mar;25(3):470-6. doi: 10.1007/s11695-014-1393-9.

PMID:
25086955
27.

The influence of prostate volume in prostate health index performance in patients with total PSA lower than 10 μg/L.

Filella X, Foj L, Alcover J, Augé JM, Molina R, Jiménez W.

Clin Chim Acta. 2014 Sep 25;436:303-7. doi: 10.1016/j.cca.2014.06.019. Epub 2014 Jun 27.

PMID:
24978824
28.

Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.

Auge JM, Pellise M, Escudero JM, Hernandez C, Andreu M, Grau J, Buron A, López-Cerón M, Bessa X, Serradesanferm A, Piracés M, Macià F, Guayta R, Filella X, Molina R, Jimenez W, Castells A; PROCOLON Group.

Gastroenterology. 2014 Sep;147(3):628-636.e1. doi: 10.1053/j.gastro.2014.06.008. Epub 2014 Jun 14.

PMID:
24937264
29.

Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection.

Foj L, Milà M, Mengual L, Luque P, Alcaraz A, Jiménez W, Filella X.

Clin Chim Acta. 2014 Aug 5;435:53-8. doi: 10.1016/j.cca.2014.04.025. Epub 2014 May 5.

PMID:
24803095
30.

Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer.

Filella X, Foj L, Augé JM, Molina R, Alcover J.

Clin Chem Lab Med. 2014 Sep;52(9):1347-55. doi: 10.1515/cclm-2014-0027.

PMID:
24695041
31.

Analytical and clinical performance of Kroma iT, a compact fully-automated immunochemistry analyzer for fecal occult hemoglobin.

Auge JM, Rodriguez C, Pellise M, Bernal A, Grau J, Castells A, Filella X, Molina R.

Anticancer Res. 2013 Dec;33(12):5633-7.

PMID:
24324109
32.

Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.

Tovar N, Fernández de Larrea C, Pedrosa F, Aróstegui JI, Cibeira MT, Rosiñol L, Elena M, Filella X, Yagüe J, Bladé J.

Ann Hematol. 2014 Jan;93(1):107-11. doi: 10.1007/s00277-013-1942-7. Epub 2013 Nov 12.

PMID:
24218189
33.

Variability of assay methods for total and free PSA after WHO standardization.

Foj L, Filella X, Alcover J, Augé JM, Escudero JM, Molina R.

Tumour Biol. 2014 Mar;35(3):1867-73. doi: 10.1007/s13277-013-1249-2. Epub 2013 Oct 4.

PMID:
24092573
34.

Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.

Gifre L, Ruiz-Gaspà S, Monegal A, Nomdedeu B, Filella X, Guañabens N, Peris P.

Bone. 2013 Nov;57(1):272-6. doi: 10.1016/j.bone.2013.08.016. Epub 2013 Aug 24.

PMID:
23981659
35.

Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution.

Tovar N, de Larrea CF, Aróstegui JI, Cibeira MT, Rosiñol L, Rovira M, Elena M, Filella X, Yagüe J, Bladé J.

Haematologica. 2013 Jul;98(7):1142-6. doi: 10.3324/haematol.2013.084350. Epub 2013 May 3.

36.

PCA3 in the detection and management of early prostate cancer.

Filella X, Foj L, Milà M, Augé JM, Molina R, Jiménez W.

Tumour Biol. 2013 Jun;34(3):1337-47. doi: 10.1007/s13277-013-0739-6. Epub 2013 Mar 16. Review.

PMID:
23504524
37.

Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis.

Filella X, Giménez N.

Clin Chem Lab Med. 2013 Apr;51(4):729-39. doi: 10.1515/cclm-2012-0410. Review.

PMID:
23154423
38.

Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.

Codony-Servat J, Marín-Aguilera M, Visa L, García-Albéniz X, Pineda E, Fernández PL, Filella X, Gascón P, Mellado B.

Prostate. 2013 Apr;73(5):512-21. doi: 10.1002/pros.22591. Epub 2012 Oct 4.

PMID:
23038213
39.

Circulating levels of HER-2/neu oncoprotein in breast cancer.

Molina R, Escudero JM, Muñoz M, Augé JM, Filella X.

Clin Chem Lab Med. 2012 Jan 4;50(1):5-21. doi: 10.1515/cclm.2011.822. Review.

PMID:
22505536
40.

Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.

Tovar N, Fernández de Larrea C, Elena M, Cibeira MT, Aróstegui JI, Rosiñol L, Filella X, Yagüe J, Bladé J.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1076-9. doi: 10.1016/j.bbmt.2012.03.004. Epub 2012 Mar 16.

41.

CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.

Molina V, Visa L, Conill C, Navarro S, Escudero JM, Auge JM, Filella X, Lopez-Boado MA, Ferrer J, Fernandez-Cruz L, Molina R.

Tumour Biol. 2012 Jun;33(3):799-807. doi: 10.1007/s13277-011-0297-8. Epub 2011 Dec 29.

PMID:
22203495
42.

Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site.

Molina R, Bosch X, Auge JM, Filella X, Escudero JM, Molina V, Solé M, López-Soto A.

Tumour Biol. 2012 Apr;33(2):463-74. doi: 10.1007/s13277-011-0275-1. Epub 2011 Dec 9.

PMID:
22161237
43.

Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases.

Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R.

Clin Chem. 2011 Nov;57(11):1534-44. doi: 10.1373/clinchem.2010.157073. Epub 2011 Sep 20.

44.

Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs.

Martinez-Olondris P, Rigol M, Soy D, Guerrero L, Agusti C, Quera MA, Li Bassi G, Esperatti M, Luque N, Liapikou M, Filella X, Marco F, de la Bellacasa JP, Torres A.

Crit Care Med. 2012 Jan;40(1):162-8. doi: 10.1097/CCM.0b013e31822d74a2.

PMID:
21926613
45.

Inflammatory impact of NOTES peritoneoscopy is not different from that of laparoscopy: a randomized comparative study in a survival porcine model.

Guarner-Argente C, Martínez-Pallí G, Navarro-Ripoll R, Córdova H, Beltrán M, Martínez-Zamora MA, Comas J, de Miguel CR, Rodríguez-D'Jesús A, Filella X, Hernández-Cera C, Lacy AM, Thompson CC, Fernández-Esparrach G.

Surg Endosc. 2012 Feb;26(2):374-80. doi: 10.1007/s00464-011-1882-z. Epub 2011 Sep 5.

PMID:
21898015
46.

Increased plasma concentrations of tumour markers in the absence of neoplasia.

Trapé J, Filella X, Alsina-Donadeu M, Juan-Pereira L, Bosch-Ferrer Á, Rigo-Bonnin R; Oncology Section of the Catalan Association of Clinical Laboratory Science.

Clin Chem Lab Med. 2011 Oct;49(10):1605-20. doi: 10.1515/CCLM.2011.694. Epub 2011 Sep 6. Review.

PMID:
21892908
47.

HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.

Molina R, Escudero JM, Augé JM, Filella X, Foj L, Torné A, Lejarcegui J, Pahisa J.

Tumour Biol. 2011 Dec;32(6):1087-95. doi: 10.1007/s13277-011-0204-3. Epub 2011 Aug 24.

48.

Active surveillance in prostate cancer: the need to standardize.

Filella X, Alcover J, Molina R.

Tumour Biol. 2011 Oct;32(5):839-43. doi: 10.1007/s13277-011-0193-2. Epub 2011 May 28. Review.

PMID:
21625940
49.

Clinical and inflammatory markers in amniotic fluid as predictors of adverse outcomes in preterm premature rupture of membranes.

Cobo T, Palacio M, Martínez-Terrón M, Navarro-Sastre A, Bosch J, Filella X, Gratacós E.

Am J Obstet Gynecol. 2011 Aug;205(2):126.e1-8. doi: 10.1016/j.ajog.2011.03.050. Epub 2011 Apr 8.

PMID:
21621184
50.

Prognostic value of IL-6 in localized prostatic cancer.

Alcover J, Filella X, Luqué P, Molina R, Izquierdo L, Augé JM, Alcaraz A.

Anticancer Res. 2010 Oct;30(10):4369-72.

Supplemental Content

Loading ...
Support Center